Research Analysts’ Weekly Ratings Changes for Charles River Laboratories International (CRL)

Several brokerages have updated their recommendations and price targets on shares of Charles River Laboratories International (NYSE: CRL) in the last few weeks:

  • 11/11/2026 – Charles River Laboratories International had its “buy” rating reaffirmed by TD Cowen. They now have a $388.00 price target on the stock.
  • 11/7/2026 – Charles River Laboratories International was upgraded by Wall Street Zen from “hold” to “buy”.
  • 11/5/2026 – Charles River Laboratories International had its price target raised by UBS Group from $357.00 to $387.00. They now have a “buy” rating on the stock.
  • 11/5/2026 – Charles River Laboratories International had its price target raised by Royal Bank Of Canada from $322.00 to $352.00. They now have an “outperform” rating on the stock.
  • 11/5/2026 – Charles River Laboratories International had its price target raised by Barclays from $330.00 to $375.00. They now have an “overweight” rating on the stock.
  • 11/2/2026 – Charles River Laboratories International was downgraded by Zacks Research from “strong-buy” to “hold”.
  • 10/12/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $300.00 to $340.00. They now have an “overweight” rating on the stock.
  • 10/2/2026 – Charles River Laboratories International was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 9/30/2026 – Charles River Laboratories International is now covered by UBS Group. They set a “buy” rating and a $357.00 price target on the stock.
  • 9/30/2026 – Charles River Laboratories International was upgraded by UBS Group to “strong-buy”.
  • 9/28/2026 – Charles River Laboratories International had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 9/28/2026 – Charles River Laboratories International had its price target raised by Jefferies Financial Group from $305.00 to $340.00. They now have a “buy” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by Deutsche Bank from $300.00 to $320.00. They now have a “buy” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International was given a new $330.00 price target by Evercore.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by TD Cowen from $300.00 to $325.00. They now have a “buy” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by Barclays from $300.00 to $330.00. They now have an “overweight” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by Royal Bank Of Canada from $282.00 to $322.00. They now have an “outperform” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by Mizuho from $264.00 to $295.00. They now have a “neutral” rating on the stock.
  • 9/25/2026 – Charles River Laboratories International had its price target raised by Robert W. Baird from $291.00 to $334.00. They now have an “outperform” rating on the stock.

Charles River Laboratories International Stock Down 1.6%

CRL stock traded down $5.32 during trading on Thursday, reaching $327.93. The stock had a trading volume of 495,054 shares, compared to its average volume of 958,070. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $379.63. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. The company’s 50 day moving average is $314.26 and its two-hundred day moving average is $230.05. The company has a market capitalization of $15.71 billion, a price-to-earnings ratio of 360.37, a P/E/G ratio of 3.00 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to analysts’ expectations of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.43 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.45 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, Director James Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 2,156 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 60,740 shares of company stock valued at $19,528,128. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

Read More

Receive News & Ratings for Charles River Laboratories International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc and related companies with MarketBeat.com's FREE daily email newsletter.